137 related articles for article (PubMed ID: 2406518)
1. Lymphokine activated killer cells: a new approach to immunotherapy of cancer.
Semenzato G
Leukemia; 1990 Feb; 4(2):71-80. PubMed ID: 2406518
[No Abstract] [Full Text] [Related]
2. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
Clark J; Longo DL
Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
[No Abstract] [Full Text] [Related]
3. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
West WH
Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
[No Abstract] [Full Text] [Related]
4. Lymphokine-activated killer lymphocytes: extramural clinical trials.
Sniecinski IJ
Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
[No Abstract] [Full Text] [Related]
5. LAK cells in cancer therapy--European results.
Sibinga CT
Prog Clin Biol Res; 1990; 337():439-41. PubMed ID: 2191334
[No Abstract] [Full Text] [Related]
6. [Immunotherapy of malignant diseases using interleukin 2. Bases, results, trends].
Gause A; Pfreundschuh M
Med Klin (Munich); 1990 Sep; 85(9):561-6, 570. PubMed ID: 2233615
[No Abstract] [Full Text] [Related]
7. Therapy with interleukin-2 and tumor-derived activated lymphocytes.
Oldham RK
Immunol Ser; 1994; 61():251-71. PubMed ID: 8011748
[No Abstract] [Full Text] [Related]
8. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
9. [Cancer immunotherapy: immunologic bases, reality and hopes].
Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F
Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapeutics as the fourth modality in cancer treatment.
Masucci G; Mellstedt H
Leukemia; 1990 Feb; 4(2):81-2. PubMed ID: 2406519
[No Abstract] [Full Text] [Related]
11. LAK cell therapy--clinical studies and future potential.
Marshall GD; Schwartzberg LS; Tauer KW; Lee P; Holbert JM; West WH
Prog Clin Biol Res; 1990; 337():555-8. PubMed ID: 2191342
[No Abstract] [Full Text] [Related]
12. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Blacklock JB; Grimm EA
Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
[No Abstract] [Full Text] [Related]
13. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects.
Hermann GG; Geertsen PF; von der Maase H; Steven K; Andersen C; Hald T; Zeuthen J
Cancer Res; 1992 Feb; 52(3):726-33. PubMed ID: 1732060
[TBL] [Abstract][Full Text] [Related]
14. [Care of advanced tumor treated by interleukin-2 and lymphokine-activated killer cells].
Wu Y; Li LC
Zhonghua Hu Li Za Zhi; 1994 Nov; 29(11):654-6. PubMed ID: 7614584
[No Abstract] [Full Text] [Related]
15. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].
Osanto S; Brand A; van Rood JJ; Cleton FJ
Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758
[No Abstract] [Full Text] [Related]
16. [Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology].
Barón Saura JM; Pizarro Redondo A; Berrocal Jaime A; González Barón M
Rev Clin Esp; 1991 May; 188(9):468-72. PubMed ID: 1896596
[TBL] [Abstract][Full Text] [Related]
17. Lymphokine-activated killer cells/tumor-infiltrating lymphocytes therapy: efficacy, toxicity, controversies.
Dutcher JP
J Clin Apher; 1990; 5(2):80-2. PubMed ID: 2404970
[No Abstract] [Full Text] [Related]
18. Cytolytic potential of peripheral blood T-lymphocytes following adoptive immunotherapy with lymphokine-activated killer cells and low-dose interleukin 2.
Yoshino I; Yano T; Murata M; Ishida T; Sugimachi K; Kimura G; Nomoto K
Cancer Res; 1991 Mar; 51(5):1494-8. PubMed ID: 1997188
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
Hercend T; Farace F; Baume D; Charpentier F; Droz JP; Triebel F; Escudier B
J Biol Response Mod; 1990 Dec; 9(6):546-55. PubMed ID: 2074441
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy of cancer.
Topalian SL; Rosenberg SA
Crit Care Med; 1990 Feb; 18(2 Suppl):S144. PubMed ID: 2298029
[No Abstract] [Full Text] [Related]
[Next] [New Search]
